Application of Biotechnology Products in Oncology

Abstract

Get full access to this article

View all access options for this article.

References

Isaacs A. , Lindenmann B. : Virus interference. I. The interferon. Proc R Soc Ser B 147:258, 1957

Balmer CM : Clinical use of biologic response modifiers in cancer treatment: An overview—Part I. The interferons. DICP Ann Pharmacother 24:761-768, 1990

Steis RG , Smith JW II , Urba WJ , et al: Resistance to recombinant interferon alfa-2a in hairy cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 318:1409-1413, 1988

Krown SE : Interferons and interferon inducers in cancer treatment. Semin Oncol 13:207-217, 1986

Houglum JE : Interferon: Mechanisms of action and clinical value. Clin Pharmacol 2:20-28, 1983

Kirkwood JM , Ernstoff MS : Interferons in the treatment of human cancer. J Clin Oncol 2:336-352, 1984

Spiegel RJ : Clinical overview of alpha interferons. Cancer 59:626-631,1987

Sarna G. , Pertchek M. , Figlin R. , et al: Phase I study of recombinant B ser 17 interferon in the treatment of cancer. Cancer Treat Rep 70:1365-1372, 1986

Hu E. , Horning SJ : Phase I study of recombinant human interferon beta in patients with advanced cancer. J Biol Response Mod 6:121-129, 1987

10.

Quesada JR , Kurzrock R. , Sherwin SA , et al: Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J Biol Response Mod 6:20-27, 1987

11.

Ernstoff MS , Trautman T. , Davis CA , et al: A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol 5:1804-1810,1987

12.

Ault BH , Stapleton FB , Gaber L. , et al: Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med 319:1397-1400, 1988

13.

Figlin RA : Biotherapy in clinical practice. Semin Hematol 26:15-24, 1989 (suppl 3)

14.

Silver RT : Interferon in the treatment of myeloproliferative diseases. Semin Hematol 27:6-14, 1990 (suppl 4)

15.

Vadhan-Raj S. , Wong G. , Gnecco C. , et al: Immunological variables as predictors of prognosis in patients with

16.

Kaposi's sarcoma and the acquired immunodeficiency syndrome. Cancer Res 46:417-425, 1986

17.

Berek JS , Hader NF , Lagasse LD , et al: Second-look laparotomy in stage III epithelial ovarian cancer: Clinical variables associated with disease status. Obstet Gynecol 64:207-212, 1984

18.

Berek JS , Hacker NJ , Lichtenstein A. , et al: Intraperitoneal recombinant α-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: A gynecologic oncology group study . Cancer Res 45:4447-4453, 1985

19.

Kinney P. , Triozzi P. , Young D. , et al: Preliminary report of a phase II trial of interferon-beta serine in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 6:86, 1987 (abstr)

20.

Sarna GP , Figlin RA , Pertcheck M. : Phase II study of betaseron (β-ser-17-interferon) as treatment of advanced malignant melanoma. J Biol Response Mod 6:375-378, 1987

21.

Lillis PK , Brown T. , Beougher K. , et al: A phase II trial of recombinant beta interferon (betaseron) in advanced colorectal cancer. Proc Am Soc Clin Oncol 6:86, 1987 (abstr)

22.

Yung Wka , Castellanos AM , Van Tassel P , et al: Recombinant interferon beta (ifn-β-ser) given intravenously in patients with recurrent malignant gliomas. Proc Am Soc Clin Oncol 7:84,1988 (abstr)

23.

Nirenberg A. , Allen J. , Packer R. , et al: Phase I/II study of iv recombinant beta-interferon (betaseron) in children with recurrent primary brain tumor (abstract). Proc Am Soc Clin Oncol 8:305, 1989 (abstr)

24.

Kaplan EH , Rosen ST , Norris D. , et al: Phase II study of recombinant human interferon gamma for the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 82:208-212, 1990

25.

Golde DW : Overview of myeloid growth factors. Semin Hematol 27:1-7, 1990 (suppl 3)

26.

Weisbart RH , Golde DW : Physiology of granulocyte and macrophage colony-stimulating factors in host defense. Hematol Oncol Clin North Am 3:401-409,1989

27.

Wallerstein R. , Deisseroth A. : Hematopoietic growth factors in cancer treatment . Princip Pract Oncol 4:1-16, 1990

28.

Vadhan-Raj S. , Keating M. , LeMaistre A. , et al: Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317:1545-1552, 1987

29.

Estey E. , Kurzrock R. , Talpaz M. , et al: Treatment of myelodysplastic syndromes with GM-CSF + ara-C. Proc Am Soc Clin Oncol 9:236a, 1990 (abstr)

30.

Antin JH , Smith BR , Holmes W. , et al: Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome . Blood 72:705-713, 1988

31.

Ganser A. , Volkers B. , Greher J. , et al: Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes: A phase I/II trial. Blood 73:31-37, 1989

32.

Thompson JA , Lee DJ , Kidd P. , et al: Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: Toxicity, pharmacokinetics, and hematological effects. J Clin Oncol 7:629-637, 1989

33.

Vadhan-Raj S. , Broxmeyer HE , Spitzer G. , et al: Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome. Blood 74:1491-1498, 1989

34.

Glaspy JA , Baldwin CG , Robertson PA , et al: Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Intern Med 109:789-795, 1988

35.

Muhm M. , Andreef M. , Geissler K. , et al: RhGM-CSF in combination with chemotherapy: A new strategy in the therapy of acute myeloid leukemia. Blood 74:117a, 1989 (suppl 1)

36.

Evans C. , Rosenfeld CS , Winkelstein'A. , et al: Perforation of an unsuspected cecal granulocytic sarcoma during therapy with granulocyte-macrophage colony-stimulating factor. N Engl J Med 322:337, 1990

37.

Antman KS , Griffin JD , Elias A. , et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319:593-598,1988

38.

Gabrilove JL , Jakubowski A. , Scher H. , et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988

39.

Bronchud MH , Scarffe JH , Thatcher N. , et al: Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56:809-813, 1987 39. Brandt SJ , Peters WP , Atwater SK , et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation . N Engl J Med 318:869-876, 1988

40.

Nemunaitis J. , Singer JW , Buckner CD , et al: Use of recombinant human granulocyte-macrophage colony-stimulating factor: A phase I-II trial . Ann Intern Med 110:976-984,1989

41.

Peters WP , Kurtzberg J. , Atwater S. , et al: Comparative effects of rHuG-CSF and rHuGM-CSF on hematopoietic reconstitution and granulocyte function following chemotherapy and autologous bone marrow transplantation (ABMT). Proc Am Soc Clin Oncol 8:181, 1989 (abstr 702)

42.

Sheridan W. , Morstyn G. , Green M. , et al: Phase II study of granulocyte colony-stimulating factor (G-CSF) in autologous bone marrow transplantation (ABMT). Proc Am Soc Clin Oncol 8:178, 1989 (abstr 691)

43.

Peters WP , Kurtzberg J. , Kirkpatrick G. , et al: GM-CSF primed peripheral blood progenitor cells coupled with autologous bone marrow transplantation will eliminate leukopenia following high dose chemotherapy. Blood 74: 50a, 1989 (suppl 1)

44.

Gianni AM , Bregni M. , Stern AC , et al: Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 2:580-585, 1989

45.

Ventura CJ , Spitzer G. , Hester J. , et al: A controlled trial of mobilized peripheral blood progenitor cells: Does their addition to autologous bone marrow transplant and growth factor cause faster hematopoietic recovery? Proc Am Soc Clin Oncol 9:9, 1990 (abstr)

46.

Nemunaitis J. , Singer JW , Buckner CD , et al: The use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure following bone marrow transplantation . Blood 76:245-253, 1990

47.

48.

Champlin RE , Nimer SD , Ireland P. , et al: Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage colony-stimulating factor. Blood 73:694-699,1989

49.

Shimosaka A. , Ogawa M. , Masaoka T. , et al: Clinical development of recombinant human G-CSF in Japan. Overview. Mol Biother 1, 1989 (abstr 19) (suppl)

50.

Vadhan-Raj S. , Buescher S. , Broxmeyer HE , et al: Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factor. N Engl J Med 319:1628-1634, 1988

51.

Bonilla MA , Gilioi AP , Ruggerio M. , et al: Effects of recombinant human granulocyte-macrophage colony-stimulating factor on neutropenia in patients with congenital granulocytopenia. N Engl J Med 320:1574-1580,1989

52.

Hammond WP , Price TH , Souza LM , et al: Treatment of cyclinc neutropenia with granulocyte-macrophage colony-stimulating factor. N Engl J Med 320:1306-1311, 1989

53.

Jakubowski AA , Souza L. , Kelly F. , et al: Effects of human granulocyte-macrophage colony-stimulating factor in a patient with idiopathic neutropenia. N Engl J Med 320:38-42, 1989

54.

Groopman JE , Mitsuyasu RT , DeLeo MJ , et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 317:593-598, 1987

55.

GlaspyJ. , Moreno J. , Mitsuyasu R. , et al: Recombinant granulocyte-macrophage colony-stimulating factor (r-met HUG), recombinant erythropoietin (r-HuEPO) and zidovudine (AZT) in patients with AIDS complicated by anemia and neotropenia. Mol Biother 1, 1989 (abstr 17) (suppl)

56.

Erard F. , Corthesy P, Nabholzm , et al: Interleukin-2 is both necessary and sufficient for the growth and differentiation of lectin-stimulated cytolytic T lymphocyte precursors . J Immunol 134:1644-1652, 1985

57.

Henney CS , Kuribayashi K. , Kern DE , et al: Interleukin-2 augments natural killer cell activity. Nature 291:335-358, 1981

58.

Shaw Are , Blackley RC , Merryweather JP , et al: Modulation of human natural killer cell activity by recombinant human interleukin-2. Cell Immunol 91:193-200, 1985

59.

Rosenberg SA , Lotze MT , Yang JC , et al: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients . Ann Surg 210:474-485, 1989

60.

Smith KA : Interleukin-2: Inception, impact, and implications. Science 240:1169-1176, 1988

61.

Sosman JA , Hank JA , Sondel PM : In vivo activation of lymphokine-activated killer activity with interleukin-2: Prospects for combination therapies. Semin Oncol 17:22-30, 1990 (suppl 1)

62.

Stotter H. , Wiebke EA , Tomita S. , et al: Cytokines alter target cell susceptibility to lysis. J Immunol 142:1767-1773, 1989

63.

Pennica D. , Nedwin GE , Hayflick JS , et al: Human tumor necrosis factor: Precursor structure, expression and homology to lymphotoxin. Nature 312:724-729, 1984

64.

Herberman RB : Interleukin-2 therapy of human cancer: Potential benefits versus toxicity. J Clin Onc o17:1-4, 1989

65.

Rosenberg SA , Lotze MT , Muul LM , et al: Progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897, 1987

66.

Rosenberg SA , Lotze MT , Muul LM , et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492, 1985

67.

Margolin KA , Rayner AA , Hawkins MJ , et al: Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines . J Clin Oncol 7:486-498,1989

68.

Kohler G. , Milstein C. : Continuous culture of fused cells secreting antibody of predefined specificity . Nature 256:495-497, 1975

69.

Haspel MV , McCabe RP , Pomato N. , et al: Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal cancer patient. Cancer Res 45:3951-3961, 1985

70.

Liu AY , Robinson RR , Hellström KE , et al: Chimeric mouse-human IgG, antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci 84:3439-3443, 1987

71.

Hamblin TJ , Cattan AR , Glennie MJ , et al: Initial experience in treating human lymphoma with a chimeric univalent derivative of monoclonal anti-idiotype antibody. Blood 69:790-797,1987

72.

Gringauz AM : Monoclonal antibodies and the war against cancer . US Pharm 60-67,1987

73.

Tami JA , Parr MD , Brown SA , et al: Monoclonal antibody technology. Am J Hosp Pharm 43:2816-2825, 1986

74.

Dillman RO : Monoclonal antibodies for treating cancer. Ann Intern Med 111:592-603,1989

75.

Houghton A. , Scheinberg D. : Monoclonal antibodies in the treatment of hemetologic malignancies. Semin Hematol 25:23-29, 1988

76.

Granger SW , Janossy G. , Francis G. , et al: Elimination of T-lymphocytes from human bone marrow with monoclonal antibodies and cytolytic complement. Br J Haematol 50:367-374, 1982

77.

Prentice HG , Blacklock HA , Janossy G. , et al: Depletion of T-lymphocytes in donor marrow prevents significant graft versus host disease in matched allogeneic leukemic marrow transplants. Lancet 1:472-476, 1984

78.

Posner MR , Calabresi P. : Immunotherapy for cancer— Current progress, future promise. Hosp Ther 53-65, 1987

79.

Jansen J. , Falkenburg Jhf , Stepan DE , et al: Removal of neoplastic cells from autologous bone marrow grafts with monoclonal antibodies. Semin Hematol 21:164-181, 1984

80.

Gilewski TA , Golomb HM : Design of combination biotherapy studies: Future goals and challenges. Semin Oncol 17:3-10, 1990 (suppl 1)